Serum Institute's Covovax to be Launched in Sep

Serum Institute's second COVID-19 vaccine is likely to be launched in September, said officials. Covovax trials finally begin in India; the vaccine is made through a partnership with Novavax and Serum Institute of India.

The world's biggest COVID-19 vaccine maker Serum Institute of India is hopeful to launch Covovax by September this year, CEO Adar Poonawalla announced on Saturday.

"Covovax trials finally begin in India; the vaccine is made through a partnership with Novavax and Serum Institute of India," said Adar Poonawalla.

COVID-19 Vaccination in India: Issues and Challenges
India’s COVID-19 vaccination program has been launched. It currently uses the vaccines Covishield and Covaxin. There are some issues and challenges that need to be overcome in order to vaccinate all Indians.

‘COVID-19 Vaccine: Covovax is the protein-based Covid-19 vaccine developed by Novavax, headquartered in the US.’

He further said that it has been tested against African and UK variants of Covid-19 and has an overall efficacy of 89 per cent. "Hope to launch by September 2021!" the CEO of world's biggest Covid-19 vaccine maker said.

In August 2020, the two companies announced an agreement under which Novavax had given SII the licence to manufacture and supply the vaccine in low- and middle-income countries.

Source-IANS

COVID-19: Diet Plan and Lifestyle Modifications for the Unlock Phase
Healthy eating habits and adherence to physical activity are required during COVID-19 lockdown. WHO has prepared a set of general tips that you could follow during the lockdown to stay fit and healthy.

COVID-19 Vaccines Show Limitations on Viral Vectors
Limited viral vector capacities are faced by AstraZeneca’s and Johnson & Johnson’s (J&J) latest wave of COVID-19 vaccines.

Pfizer COVID-19 Vaccine Less Effective Against S. African Variants
The Pfizer-BioNTech COVID-19 vaccine is effective against the original SARS-CoV-2 strain and the UK variant.